AM-0883 is a TRPC6 (Transient receptor potential canonical 6) agonist ( hTRPC6 EC 50 = 46 nM). AM-0083 can be used for the study of cardiac and renal diseases [1] [2].
In Vitro, AM-0883 can activate HEK293T cells WT TRPC6 (EC50 = 45.5 nM) and HEK293T N-terminal truncation mutant TRPC6 (Δ2–72) (EC50 = 90.2 nM)[1]. AM-0883 functionally activates the channel through specific residues at the S6/pore helix junction[1]. AM-0883 shows a significantly stronger activating effect on the V867T/L868T double mutant than on the wild-type channel[1].
References:
[1]. Bai Y, et al. Structural basis for pharmacological modulation of the TRPC6 channel. Elife. 2020 Mar 9;9:e53311.
[2]. Chubanov V, et al. Physiological functions and pharmacological targeting of transient receptor potential channels. Pharmacol Rev. 2025 Nov;77(6):100089.
In Vitro, AM-0883 can activate HEK293T cells WT TRPC6 (EC50 = 45.5 nM) and HEK293T N-terminal truncation mutant TRPC6 (Δ2–72) (EC50 = 90.2 nM)[1]. AM-0883 functionally activates the channel through specific residues at the S6/pore helix junction[1]. AM-0883 shows a significantly stronger activating effect on the V867T/L868T double mutant than on the wild-type channel[1].
References:
[1]. Bai Y, et al. Structural basis for pharmacological modulation of the TRPC6 channel. Elife. 2020 Mar 9;9:e53311.
[2]. Chubanov V, et al. Physiological functions and pharmacological targeting of transient receptor potential channels. Pharmacol Rev. 2025 Nov;77(6):100089.